Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IVSusanne Saußele, Martin C. Müller, Doris Kraemer et al.|Blood|2015Cited by 200
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicityMarkus Borner, A. Roth, J. Bernhard et al.|Annals of Oncology|2005Cited by 103
The impact of the irinotecan (IRI) schedule on quality of life in combination with capecitabine (CAP) in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer ResearchMarkus Borner, A Roth, J. Bernhard et al.|Journal of Clinical Oncology|2004Cited by 9
The impact of the irinotecan (IRI) schedule on quality of life in combination with capecitabine (CAP) in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer ResearchMarkus Borner, A. Roth, J. Bernhard et al.|Journal of Clinical Oncology|2004Cited by 0